Literature DB >> 17926276

Epidemiology of multidrug-resistant bacteria in patients with long hospital stays.

Cagri Buke1, Laurence Armand-Lefevre, Isabelle Lolom, Waafa Guerinot, Claude Deblangy, Raymond Ruimy, Antoine Andremont, Jean-Christophe Lucet.   

Abstract

OBJECTIVE: To determine rates of colonization with multidrug-resistant (MDR) bacteria (ie, methicillin-resistant Staphylococcus aureus [MRSA], vancomycin-resistant Enterococcus [VRE], extended-spectrum beta -lactamase [ESBL]-producing Enterobacteriaceae, and Acinetobacter baumannii) after prolonged hospitalization and to assess the yield of surveillance cultures and variables associated with colonization with MDR bacteria.
DESIGN: Prospective observational cohort study conducted from February 6 to May 26, 2006.
METHODS: All patients who spent more than 30 days in our university hospital (Paris, France) were included. Rectal and nasal swab samples obtained during day 30 screening were examined for MRSA, VRE, ESBL-producing Enterobacteriaceae, and A. baumannii.
RESULTS: Of 470 eligible patients, 439 had surveillance culture samples available for analysis, including 51 patients (11.6%) with a history of colonization or infection due to 1 or more types of MDR bacteria (MRSA, recovered from 35 patients; ESBL-producing Enterobacteriaceae, from 16 patients; A. baumannii, from 6 patients; and VRE, from 0 patients) and 37 patients (9.5% of the 388 patients not known to have any of the 4 MDR bacteria before day 30 screening) newly identified as colonized by 1 or more MDR bacteria (MRSA, recovered from 20 patients; ESBL-producing Enterobacteriaceae, from 16 patients; A. baumannii, from 1 patient; and VRE, from 0 patients). A total of 87 (19.8%) of 439 patients were identified as colonized or infected with MDR bacteria at day 30. Factors that differed between patients with and without MRSA colonization included age, McCabe score, comorbidity score, receipt of surgery, and receipt of fluoroquinolone treatment. Patients with ESBL-producing Enterobacteriaceae colonization were younger than patients with MRSA colonization.
CONCLUSIONS: Differences in the variables associated with MRSA colonization and ESBL-producing Enterobacteriaceae colonization suggest differences in the epidemiology of these 2 organisms. Day 30 screening resulted in a 72.5% increase in the number of patients identified as colonized with at least 1 type of MDR bacteria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17926276     DOI: 10.1086/522678

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  12 in total

1.  Network of microbial and antibiotic interactions drive colonization and infection with multidrug-resistant organisms.

Authors:  Joyce Wang; Betsy Foxman; Lona Mody; Evan S Snitkin
Journal:  Proc Natl Acad Sci U S A       Date:  2017-09-12       Impact factor: 11.205

2.  Correlation between antimicrobial consumption and resistance among Staphylococcus aureus and enterococci causing healthcare-associated infections at a university hospital in Taiwan from 2000 to 2009.

Authors:  C C Lai; C Y Wang; C C Chu; C K Tan; C L Lu; Y L Lee; Y T Huang; P I Lee; P R Hsueh
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2010-10-15       Impact factor: 3.267

3.  Carriage of multidrug-resistant bacteria among pediatric patients before and during their hospitalization in a tertiary pediatric unit in Tunisia.

Authors:  Miniar Tfifha; Asma Ferjani; Manel Mallouli; Nesrine Mlika; Saoussen Abroug; Jalel Boukadida
Journal:  Libyan J Med       Date:  2018-12       Impact factor: 1.657

4.  Colonization with Multidrug-Resistant Bacteria - On the Efficiency of Local Decolonization Procedures.

Authors:  Julia Münch; Ralf Matthias Hagen; Martin Müller; Viktor Kellert; Dorothea Franziska Wiemer; Rebecca Hinz; Norbert Georg Schwarz; Hagen Frickmann
Journal:  Eur J Microbiol Immunol (Bp)       Date:  2017-05-31

5.  Correlation between antimicrobial consumption and incidence of health-care-associated infections due to methicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococci at a university hospital in Taiwan from 2000 to 2010.

Authors:  Chih-Cheng Lai; Chen-Chen Chu; Aristine Cheng; Yu-Tsung Huang; Po-Ren Hsueh
Journal:  J Microbiol Immunol Infect       Date:  2013-12-31       Impact factor: 4.399

6.  Active surveillance for highly resistant microorganisms in patients with prolonged hospitalization.

Authors:  Guido J H Bastiaens; Tom Baarslag; Corinne Pelgrum; Ellen M Mascini
Journal:  Antimicrob Resist Infect Control       Date:  2020-01-07       Impact factor: 4.887

7.  Prevalence of urinary colonization by extended spectrum-beta-lactamase Enterobacteriaceae among catheterised inpatients in Italian long term care facilities.

Authors:  Luca Arnoldo; Roberta Migliavacca; Laura Regattin; Annibale Raglio; Laura Pagani; Elisabetta Nucleo; Melissa Spalla; Francesca Vailati; Antonella Agodi; Adriana Mosca; Carla Zotti; Stefano Tardivo; Ines Bianco; Adele Rulli; Paola Gualdi; Pietro Panetta; Carlo Pasini; Mino Pedroni; Silvio Brusaferro
Journal:  BMC Infect Dis       Date:  2013-03-06       Impact factor: 3.090

8.  Antibacterial activity of extracellular compounds produced by a Pseudomonas strain against methicillin-resistant Staphylococcus aureus (MRSA) strains.

Authors:  Viviane F Cardozo; Admilton G Oliveira; Erick K Nishio; Marcia R E Perugini; Célia G T J Andrade; Wanderley D Silveira; Nelson Durán; Galdino Andrade; Renata K T Kobayashi; Gerson Nakazato
Journal:  Ann Clin Microbiol Antimicrob       Date:  2013-06-17       Impact factor: 3.944

9.  Carriage of extended-spectrum beta-lactamase-producing enterobacteriacae among internal medicine patients in Switzerland.

Authors:  Janet Pasricha; Thibaud Koessler; Stephan Harbarth; Jacques Schrenzel; Véronique Camus; Gilles Cohen; Arnaud Perrier; Didier Pittet; Anne Iten
Journal:  Antimicrob Resist Infect Control       Date:  2013-06-12       Impact factor: 4.887

10.  Extended-spectrum beta-lactamase--producing enterobacteriaceae in the intensive care unit: acquisition does not mean cross-transmission.

Authors:  Mikael Alves; Astrid Lemire; Dominique Decré; Dimitri Margetis; Naïke Bigé; Claire Pichereau; Hafid Ait-Oufella; Jean-Luc Baudel; Georges Offenstadt; Bertrand Guidet; Frédéric Barbut; Eric Maury
Journal:  BMC Infect Dis       Date:  2016-04-13       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.